Osteoarthritis is a leading cause of pain and disability. Once described as simply a wear and tear disease, advances in research have defined a number of diverse etiopathologic inputs. A role for inflammation with synovitis related to inflammatory mediators is well accepted and presents an important therapeutic target. Advances in disease understanding allow more effective therapeutic approaches, including modalities directed to disease prevention and modification. This session will review new concepts of etiopathology, formalized therapeutic guidelines, the role of biomarkers in diagnosis and disease assessment, and the current status of potential disease–modifying agents, the “Holy Grail” of osteoarthritis therapy.
Upon completion of this session, participants should be able to:
- describe the chief epidemiologic risk factors for osteoarthritis onset
- define disease pathophysiology and relationship to clinical presentations of osteoarthritis
- delineate current approaches to symptomatic and disease modification therapy
|Moderator:||E. William St Clair, MD, Duke University Medical Center|
To see other sessions for this day, use the date buttons to the left.